These discrepancies between clinical and genetic observations (table 1) and the fact that only statins are associated with increased diabetes risk in both clinical trials and genetic analyses indicate that NOD under lipid-lowering therapy with statins might be due to direct effects of statins in non-hepatic targets, like insulin-secreting beta cells. The gene discussed is INS; the disease is diabetes mellitus.